Fosopamine(HCl)

CAS No. 135962-35-5

Fosopamine(HCl)( —— )

Catalog No. M36173 CAS No. 135962-35-5

Fosopamine(HCl) is a DRDs agonist that can be used to study hypertension.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 238 In Stock
10MG 314 In Stock
25MG 557 In Stock
50MG 707 In Stock
100MG 995 In Stock
200MG Get Quote In Stock
500MG 1981 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Fosopamine(HCl)
  • Note
    Research use only, not for human use.
  • Brief Description
    Fosopamine(HCl) is a DRDs agonist that can be used to study hypertension.
  • Description
    Fosopamine(HCl) is a DRDs agonist that can be used to study hypertension.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    GPCR/G Protein
  • Target
    Dopamine Receptor
  • Recptor
    Dopamine Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    135962-35-5
  • Formula Weight
    283.65
  • Molecular Formula
    C9H15ClNO5P
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Cl.O=P(O)(O)OC1=CC=C(C=C1O)CCNC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • GSK598809 hydrochlor...

    GSK598809 hydrochloride is a potent, selective, CNS penetrant and orally bioavailable dopamine D3 receptor antagonist with pKi of 8.9; displays >100-fold selectivity over D2 and H1 receptors.

  • Docosahexaenoic acid...

    Docosahexaenoic acid ethyl ester (Ethyl docosahexaenoate) enhances 6-hydroxydopamine-induced neuronal damage by inducing lipid peroxidation in the mouse striatum, and can be used to study oxidative diseases of the retina or neurons.

  • Sonepiprazole

    Sonepiprazole (PNU-101387G) is a selective D4 dopamine antagonist with Kis of 3.6, 10.1, 5147, and 7430 nM for rD4-Dopamine, hD4.2-Dopamine, rD2-Dopamine, and Histamine-H1 receptors, respectively.